News Canntab Therapeutics Limited Deutsche Boerse AG

Equities

TBF1

CA1377991023

Delayed Deutsche Boerse AG Other stock markets 11:30:59 05/10/2023 am IST			5-day change	1st Jan Change
0.0005 ^EUR	-.--%		-.--%	-.--%

15/04	Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding	CI
2023	Canntab Therapeutics Limited Provide an Update on Product Delivery	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding	15/04	CI
Canadian Investment Regulatory Organization Trading Halt - PILL	05/23/05	AQ
Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order	18/23/18	NE
Canntab Therapeutics Limited Provide an Update on Product Delivery	22/23/22	CI
CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO	22/23/22	AQ
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	27/23/27	CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	26/23/26	CI
IIROC Trade Resumption - PILL	22/22/22	AQ
IIROC Trading Halt - PILL	21/22/21	AQ
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2022	28/22/28	CI
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022	28/22/28	CI
CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO	23/22/23	AQ
Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market	22/22/22	MT
CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET	22/22/22	AQ
Canntab Therapeutics Limited Announces Chief Executive Office Changes	02/22/02	CI
CANNTAB ANNOUNCES CHANGE OF AUDITOR	31/22/31	AQ
Canntab Therapeutics : 2022Feb28 Q3 Interim MD&A	30/22/30	PU
Canntab Therapeutics : 2022Feb28 q3 Interim FS	30/22/30	PU
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	30/22/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Canntab Therapeutics Limited Deutsche Boerse AG

Equities

TBF1

CA1377991023

Summary

Filters